The global reverse transcriptase enzymes industry has witnessed remarkable growth and is anticipated to further expand, reaching a valuation of US$ 335.0 Million in 2022 and projected to escalate to ...
The global reverse transcriptase enzymes market is expected to reach US$ 335.0 Million in 2022. By 2032, the market for reverse transcriptase enzymes is anticipated to reach US$ 481.8 Million with a ...
EPICENTRE Biotechnologies’ MonsterScript™ Reverse Transcriptase is a processive, thermostable enzyme that completely lacks RNase H activity. The enzyme retains high activity at temperatures >50°C, and ...
The crystal structure of a human endogenous reverse transcriptase has similarities to HIV reverse transcriptase, a well-known tractable drug target, which will help design drugs to treat cancer and ...
Reverse transcriptase selection can make or break your molecular biology experiments. From thermostability to fidelity, each feature impacts cDNA yield and accuracy. Understanding your RNA quality, ...
Alzheimer's disease is the most common cause of dementia and affects more than a tenth of Americans aged 65 and older. The disease has proven difficult to develop new treatments for, and available ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results